Tyrosine and its catabolites: From disease to cancer

Acta Biochimica Polonica

Volumn 43, Issue 1, 1996, Pages 209-216

  Tanguay, Robert M ^a   Jorquera, Rossana ^a   Poudrier, Jacques ^a   St Louis, Maryse ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Fumarylacetoacetate; Fumarylacetoacetate hydrolase; Hepatocarcinogenesis; Maleylacetoacetate; Mutagenesis; Tyrosinemia type I

Indexed keywords

FUMARYLACETOACETASE; HYDROLASE; TYROSINE;

ANIMAL; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ENZYMOLOGY; GENETICS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; RECESSIVE GENE; REVIEW;

AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; GENES, RECESSIVE; HUMANS; HYDROLASES; INCIDENCE; LIVER NEOPLASMS; MICE; MICE, MUTANT STRAINS; TYROSINE;

EID: 0029691452     PISSN: 0001527X     EISSN: None     Source Type: Journal    
DOI: 10.18388/abp.1996_4530     Document Type: Article

References (33)

1. Kvittingen, E.A. (1986) Hereditary tyrosinemia type I - an overview. Scand. J. Clin. Lab. Invest. 46, 27-34.
2. Mitchell, G.A., Lambert, M. & Tanguay, R.M. (1995) Hypertyrosinemia; in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S. & Valle, D., eds.) pp. 1077-1106, McGraw-Hill, New York.
3. Lindblad, B., Lindstedt, S. & Steen, G. (1977) On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. U.S.A. 74, 4641-4645.
4. Gagné, R., Lescault, A., Grenier, A., Laberge, C., Melançon, S.B. & Dallaire, L. (1982) Prenatal diagnosis of hereditary tyrosinaemia: Measurement of succinylacetone in amniotic fluid. Prenat. Diagn. 2, 185-188.
5. Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., Paradis, K., Weber, A., Lefevre, Y, Melançon, S. & Dallaire, L. (1990) Neurological crises in hereditary tyrosinemia. N. Engl. J. Med. 322, 432-437.
6. DeBraekeleer, M. & Larochelle, J. (1990) Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am. J. Hum. Genet. 47, 302-307.
7. Grompe, M., St-Louis, M., Demers, S.I., Al-Dhalimy, M., Leclerc, B. & Tanguay, R.M. (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N. Engl. J. Med. 331, 353-357.
8. Poudrier, J., St-Louis, M., Lettre, F., Gibson, K., Prévost, C., Larochelle, J. & Tanguay, R.M. (1996) Frequency of the IVS12+5G→A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean. Prenat. Diagn. 16, 59-64.
9. Tanguay, R.M., Laberge, C., Lescault, A., Valet, J.P., Duband, J.L. & Quenneville, Y. (1984) Molecular basis of hereditary tyrosinemias, Proof of the primary defect by western blot; in Advances in Gene Technology: Human Genetic Disorders (Ahmad, F., Black, S., Schultz, J., Scott, W.A. & Whelan, W.J., eds.) pp. 256-257, ICSU, Cambridge.
10. Tanguay, R.M., Valet, J.P., Lescault, A., Duband, J.L., Laberge, C., Lettre, F. & Plante, M. (1990) Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am. J. Hum. Genet. 47, 308-316.
11. Berger, R., van Faassen, H., Taanman, J.W., Vries, H.D. & Agsteribbe, E. (1987) Type I tyrosinemia: Lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts. Pediatr. Res. 22, 394-398.
12. Agsteribbe, E., van Faassen, H., Hartog, M.V., Reversma, T., Taanman, J.-W., Pannekoek, H., Evers, R.F., Welling, G.M. & Berger, R. (1990) Nucleotide sequence of cDNA encoding human fumarylacetoacetase. Nucleic Acids Res. 18, 1887.
13. Phaneuf, D., Labelle, Y., Bérubé, D., Arden, K., Cavenee, W., Gagné, R. & Tanguay, R.M. (1991) Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15. Am. J. Hum. Genet. 48, 525-535.
14. Phaneuf, D., Lambert, M., Laframboise, R., Mitchell, C., Lettre, F. & Tanguay, R.M. (1992) Type 1 hereditary tyrosinemia: Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J. Clin. Invest. 90, 1185-1192.
15. Labelle, Y., Phaneuf, D., Leclerc, B. & Tanguay, R.M. (1993) Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum. Mol. Genet. 2, 941-946.
16. Labelle, Y., Puymirat, J. & Tanguay, R.M. (1993) Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Biochim. Biophys. Acta 1180, 250-256.
17. St-Louis, M., Leclerc, B., Laine, J., Salo, M.K., Holmberg, C. & Tanguay, R.M. (1994) Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum. Mol. Genet. 3, 69-72.
18. Grompe, M. & Al-Dhalimy, M. (1993) Mutations of the fumarylacetoacetate hydrolase gene in four patients with hereditary tyrosinemia type I. Hum. Mutat. 2, 85-93.
19. Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O. & Strandvik, B. (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340, 813-817.
20. Laberge, C., Lescault, A. & Tanguay, R.M. (1986) Hereditary tyrosinemias (type I), A new vista on tyrosine toxicity and cancer; in Essential Nutrients in Carcinogenesis (Poirier, L.A., Newberne, P.M. & Pariza, M.W., eds.) pp. 209-221, Plenum Press, New York.
21. Kelsey, G., Ruppert, S., Beermann, F., Grund, C., Tanguay, R.M. & Schutz, G. (1993) Rescue of mice homozygous for lethal albino deletions, Implications for an animal model for the human liver disease tyrosinemia type 1. Genes & Dev. 7, 2285-2297.
22. Gluecksohn-Waelsch, S. (1979) Genetic control of morphogenetic and biochemical differentiation: Lethal albino deletions in the mouse. Cell 16, 225-237.
23. Kelsey, G. & Schutz, G. (1993) Lessons from lethal albino mice. Curr. Opin. Genet. Dev. 3, 259-264.
24. Grompe, M., Al-Dhalimy, M., Finegold, M., Ou, C.-N., Burlingame, T., Kennaway, N.G. & Soriano, P. (1993) Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes & Dev. 7, 2298-2307.
25. Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N., Papaconstantinou, J., Torres-Ramos, C.A., Ou, C.-N., Burlingame, T., & Finegold, M. (1995) Pharmacological correction of neonatal lethal hepatic-dysfunction in a murine model of hereditary tyrosinemia type I. Nat. Genetics 10, 453-460.
26. Ellis, M.K., Whitfield, A.C., Gowans, L.A., Auton, T.R., Provan, W.M., Lock, E.A. & Smith, L.L. (1995) Inhibition of 4-hydroxyphenyl-pyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Toxicol. Appl. Pharmacol. 133, 12-19.
27. Fernandez-Canon, J.M. & Penalva, M.A. (1995) Fungal metabolic model for human type 1 hereditary tyrosinaemia. Proc. Natl. Acad. Sci. U.S.A. 92, 9132-9136.
28. Kvittingen, E.A., Rootwelt, H., van-Dam, T., van Faassen, H. & Berger, R. (1992) Hereditary tyrosinemia type I: Lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein. Pediatr. Res. 31, 43-46.
29. Kvittingen, E.A., Rootwelt, H., Brandtzaeg, P., Bergan, A. & Berger, R. (1993) Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect. J. Clin. Invest. 91, 1816-1821.
30. Phaneuf, D., Hadchouel, M., Tanguay, R.M., Bréchot, C. & Ferry, N. (1995) Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer. Biochem. Biophys. Res. Commun. 208, 957-963.
31. Grossman, M., Raper, S.E., Kozarsky, K., Stein, E.A., Engelhardt, J.F., Muller, D., Lupien, P.J. & Wilson, J.M. (1994) Succesful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genetics 6, 335-341.
32. Hurford, R.K., Dranoff, G., Mulligan, R.C. & Tepper, R.I. (1995) Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genetics 10, 430-435.
33. Glatt H. (1990) Endogenous mutagens derived from amino acids. Mutation Res. 238, 235-243.